Radiation oncology management of stage III and IVA cervical carcinoma

Franco, Idalid; Viswanathan, Akila N.

doi:10.1136/ijgc-2021-002491

Cited by 6 publications

(3 citation statements)

References 44 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The five-year survival rates range between 39.7% and 41.5% for stage III disease and only reach 22% for stage IVA disease. Stage IIIB is typically treated solely with radiotherapy alone, thus resulting in a five-year survival rate of 46% ( 6 ). Concurrent chemoradiotherapy has been shown to improve the five-year survival rate by approximately 6%, thus yielding an overall five-year survival rate of approximately 70%, compared to radiotherapy alone among patients with locally advanced cervical cancer ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

The research progress on radiation resistance of cervical cancer

Liang,

Sheng,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Cervical carcinoma is the most prevalent gynecology malignant tumor and ranks as the fourth most common cancer worldwide, thus posing a significant threat to the lives and health of women. Advanced and early-stage cervical carcinoma patients with high-risk factors require adjuvant treatment following surgery, with radiotherapy being the primary approach. However, the tolerance of cervical cancer to radiotherapy has become a major obstacle in its treatment. Recent studies have demonstrated that radiation resistance in cervical cancer is closely associated with DNA damage repair pathways, the tumor microenvironment, tumor stem cells, hypoxia, cell cycle arrest, and epigenetic mechanisms, among other factors. The development of tumor radiation resistance involves complex interactions between multiple genes, pathways, and mechanisms, wherein each factor interacts through one or more signaling pathways. This paper provides an overview of research progress on an understanding of the mechanism underlying radiation resistance in cervical cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

The research progress on radiation resistance of cervical cancer

Liang,

Sheng,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In the initial evaluation of many of these patients with cervical cancer, staging studies, including PET and MRI scans, assist in determining the extent of the cervical disease as well as any nodal or distant involvement of the disease [ 8 ]. Imaging is also helpful in evaluating a patient's response to treatment.…”

Section: Discussionmentioning

confidence: 99%

Dramatic Radiographic Response of Pelvis-Filling Locally Advanced Cervical Cancer Treated With Radiation and Chemotherapy

Bedi,

Kieft,

Joiner

et al. 2024

Cureus

View full text Add to dashboard Cite

Locally advanced cervical cancers are often treated with palliative intent due to concerns that the tumor is too far advanced or too large to be treated curatively. Also, patients greater than 65 years of age with cervical cancer are sometimes regarded as being too old or too frail to be cured with combined radiation and chemotherapy. These patients are often treated with radiation alone or with palliative therapy. Understanding the treatment modalities for cervical cancer is essential, as they can be complex and unique to each patient's specific diagnosis. This case report aims to describe the dramatic response to treatment with combined radiation and chemotherapy for a patient greater than 65 years of age with pelvis-filling cervical cancer with right-sided hydronephrosis. After a five-week course of concurrent chemoradiation, the cervical mass radiographically completely disappeared, with no evidence of disease noted on pelvic MRI.

show abstract

“…According to the International Federation of Gynecology and Obstetrics (FIGO), stage IVA cervical cancer (CC) is a tumor that invades the mucosa of the bladder or rectum without distant metastasis, comprising 3.1% of cases; concurrent chemoradiotherapy (CCRT), including platinum-containing chemotherapy and brachytherapy, is recommended [ 1 , 2 ]. Treatment complications can be severe, including fistula formation presented at the time of diagnosis and development during or after treatment, and the prognosis of stage IVA disease is poor; the 5-year overall survival rate ranges from 5% to 50% [ 1 , 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Successful management of locally advanced cervical cancer via total pelvic exenteration following neoadjuvant chemotherapy

Endo,

Soeda,

Yoshimoto

et al. 2024

Journal of Surgical Case Reports

View full text Add to dashboard Cite

Stage IVA cervical cancer is a tumor that invades the mucosa of the bladder or rectum without distant metastasis and is difficult to treat, and concurrent chemoradiotherapy is recommended. Although radical surgery following neoadjuvant chemotherapy is a treatment option for stage IVA cervical cancer, the evidence is limited. A 51-year-old woman with bulky cervical cancer and rectal invasion was referred to our hospital. Paclitaxel and cisplatin were administered as neoadjuvant chemotherapies. After two cycles of chemotherapy, the tumor size decreased markedly. Total pelvic exenteration was performed, and a complete resection was achieved. Four cycles of paclitaxel and cisplatin were administered postoperatively. Thirty-three months after the completion of adjuvant chemotherapy, the patient was alive and free of disease. Radical surgery after neoadjuvant chemotherapy may be a treatment option for stage IVA cervical cancer with bulky tumors.

show abstract

Radiation oncology management of stage III and IVA cervical carcinoma

Cited by 6 publications

References 44 publications

The research progress on radiation resistance of cervical cancer

The research progress on radiation resistance of cervical cancer

Dramatic Radiographic Response of Pelvis-Filling Locally Advanced Cervical Cancer Treated With Radiation and Chemotherapy

Successful management of locally advanced cervical cancer via total pelvic exenteration following neoadjuvant chemotherapy

Contact Info

Product

Resources

About